TITLE

Recombinant human erythropoietin in the treatment of anemic patients with hematological malignancies

AUTHOR(S)
Kasper, C.
PUB. DATE
June 2001
SOURCE
Annals of Hematology;Jun2001, Vol. 80 Issue 6, p319
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Patients with malignant diseases frequently develop anemia. An alternative to blood transfusions is the application of recombinant human erythropoietin. Several nonrandomized and prospective, placebo-controlled studies have demonstrated the effect and safety of erythropoietin in patients with hematological malignancies, particularly in patients with multiple myeloma and low- to intermediate-grade non-Hodgkin's lymphoma. However, in patients with myelodysplastic syndromes, the rather low response rate of erythropoietin is overcome by the combination of erythropoietin with granulocyte colony-stimulating factor. A significant acceleration of the reconstitution of erythropoiesis has been reported in allogeneic, but not in autologous bone marrow transplantation. Especially in large open-label, multicenter studies, a statistically and clinically significant improvement in quality of life independent from chemotherapeutic response or tumor type has been demonstrated. A number of simple algorithms have been proposed using the pretreatment serum erythropoietin level, transfusion requirements, and early changes in hematological parameters.
ACCESSION #
15684746

 

Related Articles

  • Autologous and allogeneic transplantation for multiple myeloma at a single centre. Couban, S; Stewart, A K; Loach, D; Panzarella, T; Meharchand, J // Bone Marrow Transplantation;4/15/97, Vol. 19 Issue 8, p783 

    We report the results of a consecutive series of patients who underwent autologous (auto) (40), allogeneic (allo) (22) or syngeneic transplantation (2) for multiple myeloma (MM) at our centre. Median age at diagnosis was 45.5 (auto) and 43 (allo) years. Most patients had stage 2 (27% auto; 27%...

  • Journal abstracts.  // Palliative Medicine;1999, Vol. 13 Issue 3, p267 

    Discusses the abstract of the study `Bone Marrow Transplantation in Multiple Myeloma,' by R.L. Schlossman and K.C. Anderson, published in a 1999 issue of `Current Opinions in Oncology.'

  • Split chimerism after allogeneic bone marrow transplantation in Chediak-Higashi syndrome. Yamazaki, S; Takahashi, H; Fujii, H; Miyamae, T; Mori, M; Fujioka, K; Funabiki, T; Yokota, S; Arai, N; Ikuta, K // Bone Marrow Transplantation;1/15/2003, Vol. 31 Issue 2, p137 

    Chediak-Higashi Syndrome (CHS) is a hereditary multiorgan disease associated with a lymphoproliferative disorder termed 'accelerated phase' (AP). As AP is often life-threatening, hematopoietic stem cell transplantation has been proposed as the only curative treatment for CHS. Here, we report a...

  • Prolonged survival after intensive therapy and purged ABMT in patients with multiple myeloma. Reece, D E; Brockington, D A; Phillips, G L; Barnett, M J; Klingemann, H-G; Nantel, S H; Sutherland, H J; Shepherd, J D // Bone Marrow Transplantation;9/15/2000, Vol. 26 Issue 6, p621 

    Despite numerous strategies, the cure of multiple myeloma remains a difficult challenge. Recent approaches have involved dose-intensive therapy followed by stem cell transplantation, most often with autologous stem cells (ASCT). Although ASCT is of benefit, it is not considered curative. Between...

  • Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Barlogie, B.; Jagannath, S.; Naucke, S.; Mattox, S.; Bracy, D.; Crowley, J.; Tricot, G.; Alexanian, R. // Bone Marrow Transplantation;6/1/98, Vol. 21 Issue 11, p1101 

    Between 1985 and 1990, 133 patients with advanced multiple myeloma (MM) (74% resistance; 41% resistant relapse, RR) were treated with five high-dose therapy (HDT) regimens including: melphalan ≤100 mg/m² (MEL 100) (46 patients); MEL 100 plus GM-CSF (24 patients); MEL 140 plus autologous...

  • Syngeneic transplantation in multiple myeloma – a case-matched comparison with autologous and allogeneic transplantation. Gahrton, G.; Svensson, H.; Björkstrand, B.; Apperley, J.; Carlson, K.; Cavo, M.; Ferrant, A.; Fouillard, L.; Gratecos, N.; Gratwohl, A.; Guilhot, F.; Deliliers, G. Lambertenghi; Ljungman, P.; Masszi, T.; Milligan, D. W.; Powles, R. L.; Reiffers, J.; Samson, J. D.; Stoppa, A. M.; Vernant, J. P. // Bone Marrow Transplantation;10/1/99, Vol. 24 Issue 7, p741 

    Twenty-five patients with multiple myeloma received bone marrow grafts (n = 24) or peripheral blood stem cells (n = 1) from twin donors. The outcome was compared in a case-matched analysis to 125 patients who underwent autologous transplantation, and 125 who underwent allogeneic transplantation....

  • Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation. Lipinski, E; Cremer, F W; Ho, A D; Goldschmidt, H; Moos, M // Bone Marrow Transplantation;11/15/2001, Vol. 28 Issue 10, p957 

    The clinical relevance of the assessment of minimal residual disease (MRD) in patients with multiple myeloma (MM) to predict disease recurrence has not been proven. In the present study, we retrospectively analyzed the tumor load in peripheral blood (PB) and bone marrow (BM) samples of 13...

  • Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Urbano-Ispizua, A.; Schmitz, N.; de Witte, T.; Frassoni, F.; Rosti, G.; Schrezenmeier, H.; Gluckman, E.; Friedrich, W.; Cordonnier, C.; Socie, G.; Tyndall, A.; Niethammer, D.; Ljungman, P.; Gratwohl, A.; Apperley, J.; Niederwieser, D.; Bacigalupo, A. // Bone Marrow Transplantation;4/15/2002, Vol. 29 Issue 8, p639 

    Focuses on the definitions and practice of allogeneic and autologous transplantation for haematological diseases, solid tumors, and immune disorders in Europe. Categorization of transplant procedures; Status of transplants in specific diseases in adults; Indication of using haploidentical...

  • A pharmacological approach to dry eye syndrome in GVHD. Grob, Seanna; Dana, Reza // Ophthalmology Times;11/15/2014, Vol. 39 Issue 21, p6 

    A 65-YEAR-OLD MALE with history of multiple myeloma and acute myeloid leukemia now status post multiple bone marrow transplants (including two allogeneic and 2 autologous transplants) presented for evaluation of dry eye symptoms and photophobia that worsened after stopping oral Tacrolimus, which...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics